Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules

Journal of the National Cancer Institute

Volumn 92, Issue 15, 2000, Pages 1228-1239

  Hodge, James W ^a   Rad, Ariel N ^b   Grosenbach, Douglas W ^a   Sabzevari, Helen ^a   Gómez Yafal, Alicia ^c   Gritz, Linda ^c   Schlom, Jeffrey ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Therion Biologics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LIPOPOLYSACCHARIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; OVALBUMIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; EFFECTOR CELL; FEMALE; FOWLPOX VIRUS; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS;

EID: 0034596362     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.15.1228     Document Type: Article

References (67)

1. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes
2. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles
3. The role of B7-1 and LFA-3 in costimulation of CD8+ T cells
4. Costimulatory requirements of naive CD4+ T cells ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response
5. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response
6. A triad of costimulatory molecules synergize to amplify T-cell activation
7. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases
8. Dendritic cells: A link between innate and adaptive immunity
9. Immunotherapy of cancer with dendritic-cell-based vaccines
10. Experimental vaccine strategies for cancer immunotherapy
11. Dendritic cell based therapy of cancer
12. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells
13. Induction of CD8+ cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells
14. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th 1-biasing cytokines
15. CTL response to Mycobacterium tuberculosis: Identification of an immunogenic epitope in the 19-kDa lipoprotein
16. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae
17. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus
18. Exact prediction of a natural T cell epitope
19. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes
20. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
21. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
22. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus
23. Compact, synthetic, vaccinia virus early/ late promoter for protein expression
24. Sequence and transcriptional analysis of the vaccinia virus HindIII I fragment
25. Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene
26. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity
27. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21
28. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
29. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation
30. Induction and measurement of cytotoxic T lymphocyte activity
31. Fowlpox virus host range restriction: Gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells
32. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation
33. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
34. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL
35. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
36. Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death
37. Dendritic cell maturation is required for initiation of the immune response
38. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
39. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells
40. Comparative analysis of murine dendritic cells derived from spleen and bone marrow
41. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
42. Dendritic cells require maturation via CD40 to generate protective antitumor immunity
43. Expression of B7 costimulator molecules on mouse dendritic cells
44. Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1 dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes
45. Bcl-2 and the regulation of programmed cell death
46. Protease activation during apoptosis: Death by a thousand cuts?
47. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures
48. Induction of antitumor immunity using bone marrow-generated dendritic cells
49. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
50. Autoimmune disease induced by dendritic cell immunization against leukemia
51. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors
52. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides
53. Immunization with CEA agonist epitope pulsed FLT3L expanded dendritic cells for human tumor immunotherapy
54. Dendritic cell-based immunotherapy of renal cell carcinoma
55. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
56. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
57. Efficient retrovirus-mediated gene transfer of dendritic cells generated from CD34+ cord blood cells under serum-free conditions
58. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
59. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity
60. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
61. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells
62. Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors
63. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria
64. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses
65. Vaccinia virus goes through an abortive replication cycle in dendritic cells and inhibits their maturation
66. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine
67. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates